Search Results for "tioconazole"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for tioconazole. Results 1 to 5 of 5 total matches.
See also: Vagistat

Topical Drugs For Vaginal Candidiasis

   
The Medical Letter on Drugs and Therapeutics • Aug 23, 1991  (Issue 851)
Tioconazole Vagistat − Bristol-Myers Squibb 6.5% ointment 4.6 grams at bedtime once 4.6 gm − 16.95 ...
Many drugs, mostly imidazole derivatives, are marketed in the USA for topical treatment of vulvovaginal candidiasis, and a few are now available without a prescription.
Med Lett Drugs Ther. 1991 Aug 23;33(851):81 |  Show IntroductionHide Introduction

Drugs For Vulvovaginal Candidiasis

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2001  (Issue 1095)
suppository at bedtimex3days 3supps − 32.23 Tioconazole 6.5% cream 4.6 grams at bedtime once Monistat 1 ...
Many drugs, mostly azole derivatives, are marketed in the USA for topical treatment of vulvovaginal candidiasis. A single-dose, sustained-release formulation of butoconazole nitrate 2% cream (Gynazole 1) is the newest addition. Fluconazole (Diflucan) is approved for single-dose oral treatment.
Med Lett Drugs Ther. 2001 Jan 8;43(1095):3-4 |  Show IntroductionHide Introduction

Oral Fluconazole for Vaginal Candidiasis

   
The Medical Letter on Drugs and Therapeutics • Sep 16, 1994  (Issue 931)
x 3 days 3 supps − 22.26 0.8% cream 5 grams at bedtime x 3 days 20 gm − 22.26 Tioconazole ...
Many drugs, mostly imidazole derivatives, are marketed in the USA for topical treatment of vulvovaginal candidiasis (Medical Letter, 33:81, 1991). Recently, fluconazole (Diflucan - Roerig), which is the drug of choice for treatment of oropharyngeal and esophageal candidiasis (Medical Letter, 36:16, 1994), was approved by the US Food and Drug Administration for single-dose oral treatment of .
Med Lett Drugs Ther. 1994 Sep 16;36(931):81-2 |  Show IntroductionHide Introduction

Ibrexafungerp (Brexafemme) for Vulvovaginal Candidiasis

   
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021  (Issue 1632)
. Letter ibrexafungerp Monistat terconazole Tioconazole Vagistat Vulvovaginal candidiasis Gyne-Lotrimin ...
The FDA has approved ibrexafungerp (Brexafemme – Scynexis), a first-in-class triterpenoid antifungal ("fungerp"), for oral treatment of vulvovaginal candidiasis in postmenarchal females.
Med Lett Drugs Ther. 2021 Sep 6;63(1632):141-3 |  Show IntroductionHide Introduction

Antifungal Drugs

   
Treatment Guidelines from The Medical Letter • Aug 01, 2012  (Issue 120)
, tioconazole, terconazole 1x/d x 1-14 d11 or Fluconazole 150 mg PO once12 Itraconazole 200 mg PO bid x 1d ...
The drugs of choice for treatment of fungal infections are listed in the table that begins on page 62. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines for some of these infections are available online from the Infectious Diseases Society of America (www.idsociety.org).
Treat Guidel Med Lett. 2012 Aug;10(120):61-8 |  Show IntroductionHide Introduction